HighGravityData

Boston Scientific

Guidance from Boston Scientific’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Current guidance
6 items
Releases tracked
8
Latest release
Jul 29, 2026
Data checked
Jul 29, 2026
On this page:Latest changes·Current guidance·Your sector group·History

What changed in the Jul 29, 2026 release

Each item compared with the same item in the previous release (Apr 22, 2026). Values in quotation marks are the company’s words.

New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
ChangeMetricPeriodPreviousNowSource
LoweredNet sales growth, organic basisfor FY2026“6.5 to 8.0 percent”“5 to 6 percent”Filing ↗
NewNet sales growth, reported and organic basisfor Q3 FY2026—“approximately 3 to 5 percent”Filing ↗
LoweredNet sales growth, reported basisfor FY2026“approximately 7.0 to 8.5 percent”“approximately 5.5 to 6.5 percent”Filing ↗
LoweredAdjusted EPSfor FY2026“$3.34 to $3.41”“$3.28 to $3.32”Filing ↗
NewAdjusted EPSfor Q3 FY2026—“$0.80 to $0.82”Filing ↗

Current guidance

Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.

Current fiscal year
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Net sales growth, organic basis“5 to 6 percent”for FY2026Company-definedFeb 4, 20263Filing ↗
Net sales growth, reported and organic basis“approximately 3 to 5 percent”for Q3 FY2026Company-definedJul 29, 20261Filing ↗
Net sales growth, reported basis“approximately 5.5 to 6.5 percent”for FY2026GAAP-tiedFeb 4, 20263Filing ↗
Adjusted EPS“$3.28 to $3.32”for FY2026Company-definedFeb 4, 20263Filing ↗
Adjusted EPS“$0.80 to $0.82”for Q3 FY2026Company-definedJul 29, 20261Filing ↗
Impact of foreign currency fluctuations“(0.5)%”for FY2026Company-definedFeb 4, 20261Filing ↗

How one item moved

Net sales growth, organic basis, for FY2025 — every statement across the year, each linked to its filing.

Feb 5, 2025
New
“approximately 10 to 12 percent”
Apr 23, 2025
Raised
“12 to 14 percent”
Jul 23, 2025
Raised
“14 to 15 percent”
Oct 22, 2025
Raised
“approximately 15.5 percent”

How your Medical devices & equipment sector group guides

12 companies in Medical devices & equipment. What they guide on, and who reported this season.

Most-guided metric families
Revenue
9
Organic growth
8
Adjusted EPS
8
Buybacks
6
GAAP EPS
5
Operating margin
4
Dividends
3
Gross margin
2
This season’s releases
MedtronicSep 1, 20263 changes
Becton DickinsonAug 6, 20264 changes
ResMedAug 6, 20260 changes
InsuletAug 5, 202625 changes
Zimmer BiometAug 5, 20263 changes
DexComJul 30, 20263 changes
StrykerJul 30, 20262 changes
Boston ScientificJul 29, 20265 changes
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Full history

Every metric, every release, eight quarters — the complete record as one table.

MetricFY2026FY2025FY2024
Net sales - Operational growth——1 statement
Net sales growth (organic basis)1 statement1 statement3 statements
Net sales growth (reported basis)1 statement1 statement2 statements
Net sales growth, organic basis4 statements7 statements—
Net sales growth, reported and organic basis1 statement——
The full record for Boston Scientific and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.

Filings

The 8 earnings releases this page is built from.

FiledFiscal periodAccessionGuidance items
Jul 29, 2026FY2026 Q20000885725-26-0000515Open filing ↗
Apr 22, 2026FY2026 Q10000885725-26-0000316Open filing ↗
Feb 4, 2026FY2025 Q40000885725-26-0000068Open filing ↗
Oct 22, 2025FY2025 Q30000885725-25-00004614Open filing ↗
Jul 23, 2025FY2025 Q20000885725-25-00003912Open filing ↗
Apr 23, 2025FY2025 Q10000885725-25-0000238Open filing ↗
Feb 5, 2025FY2024 Q40000885725-25-0000078Open filing ↗
Oct 23, 2024FY2024 Q30000885725-24-00007010Open filing ↗
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error